Lin George, Doyle Leona A
From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania (Dr Lin); and the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Doyle).
Arch Pathol Lab Med. 2015 Jan;139(1):106-21. doi: 10.5858/arpa.2014-0488-RA.
During the last 5 to 10 years, significant progress has been made in the molecular characterization of soft tissue tumors, predominantly with the identification of recurrent translocations or amplification of certain genes in different tumor types. Alongside this, translational efforts have identified many novel and diagnostically useful immunohistochemical markers for many of these tumor types.
This article reviews a select group of recently described immunohistochemical markers of particular use in the evaluation of mesenchymal neoplasms; the underlying biology of the protein product, practical utility, and limitations of each marker are discussed in detail.
Literature review, authors' research data, and personal practice experience serve as sources.
There are many diagnostically useful immunohistochemical markers to help confirm the diagnosis of many different soft tissue tumor types, some of which have reduced the need for additional, and more costly, studies, such as fluorescence in situ hybridization. However, no one marker is 100% specific for a given tumor, and knowledge of potential pitfalls and overlap in patterns of staining among other tumor types is crucial to ensure the appropriate application of these markers in clinical practice.
在过去5至10年中,软组织肿瘤的分子特征研究取得了重大进展,主要是在不同肿瘤类型中鉴定出了复发性易位或某些基因的扩增。与此同时,转化研究已经为许多这类肿瘤类型鉴定出了许多新型且具有诊断价值的免疫组化标志物。
本文综述了一组最近描述的、在间叶性肿瘤评估中特别有用的免疫组化标志物;详细讨论了每种标志物的蛋白质产物的潜在生物学特性、实际应用价值及局限性。
文献综述、作者的研究数据以及个人实践经验。
有许多具有诊断价值的免疫组化标志物可帮助确诊多种不同类型的软组织肿瘤,其中一些标志物减少了对诸如荧光原位杂交等额外且成本更高的检查的需求。然而,没有一种标志物对特定肿瘤具有100%的特异性,了解其他肿瘤类型之间潜在的陷阱和染色模式的重叠对于确保这些标志物在临床实践中的正确应用至关重要。